Nuala Moran

Four university researchers who cast off the cosy embrace of academe at a fringe meeting at the ESOF conference in Barcelona this week.

Biofuels’ fall from grace must not be allowed to undermine research into sustainable, climate-friendly, second-generation biofuels.

Slovenia has done much ito advance causes in which Science|Business and its readers take an interest. The French Presidency must maintain this momentum.

Supreme Court Rulings and patent reform are making it harder to defend patents in the US – and biotechs are falling back on trade secrets to protect their IP.

The tightening financial scene presents fresh perils for start-ups. Experts gathered together by the a UK regional biotech initiative suggest some coping strategies, Nuala Moran discovers.

Turmoil in the financial markets is having a disproportionate impact on biotech – and coupled with extra caution from regulators, is threatening innovation.

A long-time Cinderella, the biotechnology sector in Italy now has a turnover of more than 10 billion euros. It may now be poised to make its mark internationally.

In 2007, the UK’s largest retail chemists chain set up a dedicated centre at Swansea University to promote open innovation. One year on, the first product is about to hit the market.

The controversy over embryonic stem cell research will not dissipate until the technology proves itself in the clinic. Now the regulators have to move, say Science|Business’s Nuala Moran.

Ireland’s largest-ever healthcare venture capital fund is making its optimistic debut as one of the UK’s longest-standing VC supporters of high tech start-ups calls it quits. So what’s happening?